Press Releases

2024

DateTitleDownload Link
12/16/2024Cannara Provides Update on Its 2024 Annual General Meeting Materials amid Canada Post Strike
12/12/2024Cannara Biotech to Host Investor Webcast on Thursday December 19th, 2024
11/25/2024Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results:
Achieves Record Sales Growth and Operating Cash Flow
08/16/2024Cannara Biotech Achieves its Highest National Market Share
07/23/2024Cannara Biotech Reports Q3 2024 Financial Results
04/29/2024Cannara Biotech Reports Q2 2024 Financial Results
01/30/2024Cannara Biotech Announces Record-Breaking Q1 2024 Results: Continued Robust Growth and Market Expansion

DateTitleDownload Link
12/13/2023Cannara Biotech Announces Notice Of Annual General Meeting Of Shareholders To Be Held Virtually On January 25th, 2024
12/11/2023Cannara Biotech to Host Investor Webcast on Thursday December 14th, 2023
12/7/2023Cannara Biotech Reports Fourth Quarter and 2023 Fiscal Year Results: Record Growth and Profitability Continues
07/28/2023Cannara Biotech Inc. Reports Record Q3 2023 Financial Results with Net Revenues of $15.9 Million and Net Income of $2.9 million
05/11/2023Cannara Biotech Inc. To Participate At Canaccord Genuity’s 7th Annual Global Cannabis Conference
04/25/2023Cannara Biotech Inc. to Host Investor Webcast on May 4th, 2023
04/24/2023Cannara Biotech Inc. reports Q2 2023 Financial Results with quarterly net revenues of $13 million, a 76% increase compared to Q2 2022
02/10/2023Cannara biotech inc. Announces results of annual shareholder meeting and conversion into equity of a $5m convertible debenture at $0.18 cent per common share
01/23/2023Cannara Biotech Inc. Reports Q1 2023 Financial Results
01/12/2023Cannara Announces Proposed Share Consolidation

DateTitleDownload Link
11/30/2022Cannara Announces Normal Course Issuer Bid for Common Shares of the Corporation
11/25/2022Cannara Biotech Inc. Reports Record Q4 and 2022 Fiscal Year Financial Results
09/30/2022Cannara Releases 14 New SKU’s Across Ontario and Quebec
09/20/2022Cannara Biotech Inc. Announces Entry into the British Columbia Market and the Launch of its First Vape Cartridge and Vape Accessory, Tribal G Mint and UNI Pro Ark
09/01/2022Acquisition of Common Shares of Cannara Biotech Inc.
08/10/2022Cannara Biotech Inc. to Host Investor Webcast on August 17th, 2022
08/03/2022Cannara signs an Exclusive Brand Partnership with Exotic Genetix in Canada
07/27/2022Cannara Biotech Inc. Reports Fiscal Third Quarter 2022 Financial Results
06/01/2022Cannara Biotech Inc. Closes $50 Million Credit Facility Led by BMO Commercial Banking
05/04/2022Cannara Biotech Inc. to Present at Canaccord Genuity’s 6th Annual Cannabis Conference on May 11th and Retains Bristol Capital for Investor Relations Services
04/27/2022Cannara Biotech Inc. Reports Fiscal Second Quarter 2022 Financial Results
01/20/2022Cannara Biotech Inc. Reports Fiscal First Quarter 2022 Financial Results

DateTitleDownload Link
12/08/2021Cannara Biotech Inc. Reports Fourth Quarter and Fiscal Year 2021 Results
12/01/2021Cannara Biotech Inc. upsizes CIBC Credit Facility to $22 Million
09/27/2021Cannara’s Valleyfield Facility Receives Processing and Cultivation License
09/02/2021Cannara Biotech Inc. Receives Amendment of its Licence from Health Canada Permitting the Sale of Cannabis 2.0 Products and Prepares for the Launch of its Hash Product Line in Quebec
07/28/2021Cannara Biotech Inc. Reports Strong First Quarterly Profit Driven by Retail Debut
07/09/2021Cannara Biotech Inc. Completes Additional $5 Million Private Placement
06/28/2021Cannara Biotech Inc. Reports Preliminary Results Ahead of Third Quarter 2021
06/23/2021Cannara Biotech Inc. Completes Acquisition of TGOD’s State-of-the-art Cultivation and Manufacturing Facility in Valleyfield, Quebec
06/10/2021Cannara Biotech Inc. Enters into Definitive Agreement to Acquire TGOD’s State-of-the-Art Cultivation and Manufacturing Facility in Valleyfield, Quebec
04/28/2021Cannara Biotech Delivers Strong Q2 2021 Results
04/07/2021Cannara Biotech Commences Trading on TSXV on April 8, 2021
03/11/2021Cannara Biotech Secures Conditional Approval to List on the TSX Exchange
02/25/2021Cannara Biotech Launches Cannabis Brand Portfolio Now Available in Quebec – Tribal, Nugz, Orchid CBD
01/29/2021Cannara Biotech Inc. Reports Q1 2021 Financial Results
01/08/2021Cannara Biotech Receives Sales Licence from Health Canada

DateTitleDownload Link
12/15/2020Cannara Biotech Inc. (CSE: LOVE) announces Year-End and Q4 2020 Results
11/05/2020Cannara Biotech Inc. Appoints Donald Olds to Board of Directors
07/27/2020Cannara Biotech Inc. Reports Q3 2020 Financial Results
07/07/2020Cannara Completes Acquisition of Global shopCBD.com
07/06/2020Cannara enters LOI with SQDC for Entire First Year Production
05/27/2020Cannara Proposes Agreement to Acquire Global shopCBD.com
05/15/2020Cannara Biotech Inc. appoints Mary Durocher as New Board Director
04/20/2020Cannara Harvests First Crop on 420
04/16/2020Cannara Biotech Inc. Reports Q2 2020 Financial Results
02/20/2020Cannara Insiders Form Buying Group to Fully Acquire FSD/FV Pharma’s Position in Cannara
01/31/2020Cannara Biotech’s Farnham Facility Receives Cultivation Licence
01/20/2020Cannara Biotech Reports Q1 2020 Financial Results

DateTitleDownload Link
11/26/2019Cannara Biotech Reports Q4 and Year-End 2019 Financial Results
10/10/2019Cannara Biotech Secures $6 Million Mortgage Financing Facility with Canadian Imperial Bank of Commerce
07/12/2019Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares

Cannara Biotech Inc.

We stop at nothing to create products that start with one key ingredient, purposefully cultivated premium cannabis flower.

Facebook-f Instagram X-twitter Linkedin Discord
© 2024 Cannara Biotech Inc. All Rights Reserved.
Privacy Policy.

Social Media Policy

Website Design & Development by CryoDragon Inc.